Table 2.
Summary of published clinical trials using neural stem cells in spinal cord injury patients in literature
| Study | Country | Clinical phase | Injury location | Treatment timing | Cell type | Cell source | Administration route | Results |
|---|---|---|---|---|---|---|---|---|
| Moviglia et al. [107] 2009 | Argentina | Phase I | Cerivcal/thoracic | Chronic* | Autologous NSCs | Feeding artery infusion | Functional recovery was shown in 5/8 patients. | |
| Shin et al. [108] 2015 | South Korea | Phase I/II | Cervical | 22–213 days after SCI | hNSPCs | Human fetal brain | Intralesional injection | Partial improvements in sensorimotor function |
| Ghobrial et al. [105] 2017 | USA | Phase II | Cervical/thoracic | At least 4 months after SCI | NSCs (HuCNS-SC) | Human fetal brain | Intralesional injection | Improvements in overall mean functional outcomes measures |
| Levi et al. [112] 2018 | USA | Phase I | Cervical/thoracic | 4–24 months after SCI | NSCs (HuCNS-SC) | Human fetal brain | Intralesional injection | A manual injection technique are safe and feasible |
| Curtis et al. [113] 2018 | USA | Phase I | Thoracic | 1–2 years after SCI | NSCs (NSI-566) | Human fetal spinal cord | Intralesional injection | Can be transplanted safely |
| Levi et al. [106] 2019 | USA | Phase II | Cervical | 4–24 months after SCI | NSCs (HuCNS-SC) | Human fetal brain | Intralesional injection | Motor functional gains in the treated participants |
HuCNS-SC, human fetal-derived central nervous system neural stem cell; NSCs, neural stem cells; NSI-566, NSI-566 cell line human spinalcord-derived neural stem cell; hNSPCs, human neural stem/progenitor cells; SCI, spinal cord injury; USA, United States of America.
*
Specific treatment timing after spinal cord injury was not described.